Last reviewed · How we verify
TCA IR 40
TCA IR 40 is a local anesthetic that works by blocking nerve signals.
TCA IR 40 is a local anesthetic that works by blocking nerve signals. Used for Postoperative pain management.
At a glance
| Generic name | TCA IR 40 |
|---|---|
| Also known as | Kenalog®-40, Kenacort-A 40, Triamcinolone Acetonide Crystalline Suspension (TAcs), Kenalog®-40 Injection |
| Sponsor | Pacira Pharmaceuticals, Inc |
| Drug class | Local anesthetic |
| Target | Sodium channels |
| Modality | Small molecule |
| Therapeutic area | Pain management |
| Phase | Phase 3 |
Mechanism of action
It does this by inhibiting the sodium channels in nerve cells, which prevents the transmission of pain signals to the brain. This results in a temporary loss of sensation in the affected area.
Approved indications
- Postoperative pain management
Common side effects
- Numbness
- Dizziness
- Headache
Key clinical trials
- Knee Osteoarthritis Treatment With Zilretta vs. Kenalog in the Context of Type II Diabetes (PHASE4)
- Study of FX006 for the Treatment of Pain in Patients With Osteoarthritis of the Knee (PHASE3)
- Study of FX006 in Patients With Osteoarthritis of the Knee (PHASE2)
- Pharmacokinetic and Pharmacodynamic Study of FX006 in Patients With Osteoarthritis of the Knee (PHASE2)
- Study to Compare Exposure of TA Following Administration of FX006 or TAcs in Patients With OA of the Shoulder or Hip (PHASE2)
- Study to Characterize the Local Duration of Exposure From FX006 in Patients With Osteoarthritis of the Knee (PHASE2)
- Study to Assess the Effects of FX006 on Blood Glucose in Patients With OA of the Knee and Type 2 Diabetes (PHASE2)
- Proof of Concept Study Comparing FX006 to Kenalog®-40 in Patients With Post-Traumatic Osteoarthritis of the Knee (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TCA IR 40 CI brief — competitive landscape report
- TCA IR 40 updates RSS · CI watch RSS
- Pacira Pharmaceuticals, Inc portfolio CI